Overview

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease

Status:
Completed
Trial end date:
2023-12-12
Target enrollment:
Participant gender:
Summary
This study will assess the effect of severe kidney impairment on the pharmacokinetics (PK), safety and tolerability of Leritrelvir.
Phase:
Phase 1
Details
Lead Sponsor:
Guangdong Raynovent Biotech Co., Ltd